Printout from Pearl Cohen Zedek Latzer Baratz

News / Jul 24, 2019

Humanigen Secures Exclusive Worldwide License for the Prevention of GvHD through GM-CSF Neutralization from the University of Zurich

Search By

  News & Publications
Humanigen, Inc., (HGEN) (“Humanigen”) announced that it has secured an exclusive worldwide license agreement from the University of Zurich (UZH) for technology used to prevent GvHD through GM-CSF neutralization.  The technology was recently featured in a publication in Science Translational Medicine entitled “Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells”1. The Humanigen license covers various patent applications filed by UZH which complement and broaden Humanigen’s leadership position in the application of GM-CSF and expand Humanigen’s development platform to include improving allogeneic HSCT. 
 
https://www.proactiveinvestors.com/companies/stocktube/14161/humanigen-inks-licensing-agreement-with-the-university-of-zurich-to-strengthen-its-treatment-of-graft-versus-host-disease-in-leukemia-patients-14161.html
 
Mark Cohen, Senior Partner and Chair of the Life Science Practice Group represents Humanigen, Inc. in its intellectual property and commercial transactional matters. 

Read these items